Niagara Falls

Researchers are evaluating a program that integrates Community Health Workers CHWs into community pharmacies in under-resourced areas of Western New York to address social needs. This study uses a quasi-experimental design to compare outcomes between patients who receive social needs screenings and referrals and those who do not within the same healthcare system. In this study, community pharmacies distribute social needs screening surveys to patients and refer those with identified needs to local community-based organizations. Patients are grouped into those who receive no intervention and those who receive screenings and referrals. The study focuses on pharmacies enrolled in the Community Pharmacy Enhanced Services Network - NY or associated with Tops Pharmacies in Erie County. Participants will be adults aged 18 years or older who visit participating pharmacies. Researchers will monitor the effectiveness of the social needs screening and referral program over 12 months, including cost analysis. The study involves collecting information through surveys and tracking referrals to community resources, with ongoing evaluation of outcomes related to social needs status.

Researchers are evaluating the effects of YB-101 on thyroid function in adults with Graves Disease. The study aims to assess how safe and well tolerated YB-101 is, as well as how it is distributed in the body. This Phase 2 trial includes participants with a documented diagnosis of Graves Disease confirmed by thyroid-stimulating hormone receptor antibodies. The study has two parts Part 1 is a blinded treatment period and Part 2 is a double-blinded treatment period. Participants will receive either YB-101 or a placebo through subcutaneous injections over a 24-week period. Those who participate in Part 1 are not eligible to participate in Part 2. The treatments and placebo are administered similarly in both parts. Participants will attend between 34 to 39 in-clinic visits over approximately 40 weeks depending on their assigned part. Researchers will monitor side effects, safety, and thyroid hormone levels including free triiodothyronine FT3, free thyroxine FT4, and thyroid-stimulating hormone TSH. They will also evaluate the proportion of participants who normalize these hormones and stop anti-thyroid drugs. The study includes safety assessments up to Day 169 and ongoing monitoring throughout the treatment period.

Researchers are evaluating olpasiran, compared to a placebo, to see how it affects the risk of coronary heart disease death, heart attacks, or urgent coronary revascularization in people at risk for their first major cardiovascular event who have high levels of lipoproteina. This Phase 3 study focuses on participants aged 50 to 105 years with multiple cardiovascular risk factors or evidence of atherosclerosis. Participants will be randomly assigned to receive either olpasiran or a placebo through subcutaneous injections. The study is double-blind, so neither participants nor researchers know who receives the active drug or placebo. Treatments and evaluations will continue for up to approximately 6.2 years. Throughout the study, participants will be monitored for heart-related events such as heart attacks, cardiovascular death, strokes, and coronary revascularizations. Researchers will also measure changes in lipoproteina levels at baseline and at Week 48, along with tracking adverse events. The total participation duration can extend up to about 6.2 years, with ongoing assessments to evaluate the treatments effect over time.